Safety of Disease-Modifying Therapies for Highly Active Relapsing-Remitting Multiple Sclerosis

Keyphrases

• Adverse Events 30%
• Alemtuzumab 60%
• Anti-trafficking 30%
• Cholesterol 10%
• Cladribine Tablets 60%
• Clinical Outcomes 10%
• Clinical Treatment 10%
• Corticosteroids 10%
• Disability 10%
• Disease Activity 10%
• Disease Reactivation 30%
• Disease-modifying Therapy 100%
• EDSS Score 10%
• Exit Strategy 10%
• Fingolimod 60%
• Finland 10%
• Headache 10%
• Hepatobiliary 10%
• Herpes Simplex 10%
• High Disease Activity 10%
• High-density Lipoprotein Cholesterol (HDL-C) 10%
• Immune Reconstitution 30%
• Immune-related Adverse Events 10%
• Inflammatory Diseases 10%
• Infusion Reaction 20%
• Lipid Concentration 10%
• Lipid Profile 10%
• Lipoproteins 10%
• Low-density Lipoprotein 10%
• Malignancy 10%
• Median Time 10%
• Medication-related Harm 10%
• Multiple Sclerosis 30%
• Multiple Sclerosis Treatment 20%
• Natalizumab 50%
• Natalizumab Discontinuation 20%
• Nausea 10%
• Neurological Impairment 10%
• Overall Risk 10%
• Patient Data 10%
• Patient Information 10%
• Postmarketing 10%
• Real Patients 10%
• Relapsing-remitting multiple Sclerosis 100%
• Risk Factors 10%
• Safety Concerns 10%
• Safety Issues 10%
• Serious Adverse Events 10%
• Specific Intent 10%
• Subgroup Analysis 10%
• Time to First Relapse 10%
• Treatment Sequence 10%
• Treatment Study 20%
• Triglycerides 10%
• Washout Period 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 35%
• Alemtuzumab 42%
• Atherosclerosis 14%
• Cladribine 42%
• Disease Activity 7%
• Diseases 100%
• Expanded Disability Status Scale 7%
• Fingolimod 42%
• Headache 7%
• Herpes Simplex 7%
• High Density Lipoprotein 7%
• Infection 7%
• Inflammatory Disease 7%
• Lipoprotein 7%
• Low Density Lipoprotein 7%
• Multiple Sclerosis 100%
• Natalizumab 50%
• Nausea 7%
• Tablet 42%
• Triacylglycerol 7%